

Certificate of Analysis

Product: DOAC-Remove 20 (A) or 50 (B) or 250 (C) tablets

Art. No.: 5D-82410A/B/C

Lot: 826100

Expiration Date: 2023-06-29

Description: DOAC-Remove™ tablets are intended to be used for removal of Direct Oral Anticoagulants (DOACs) compounds from human citrated plasma samples, including dabigatran, rivaroxaban, apixaban and edoxaban. Also removes argatroban. DOAC-Remove™ reduces the false positivity for lupus anticoagulants tests on DOAC-containing plasmas and is useful for eliminating interference of DOACs on routine coagulation assays such as APTT, PT, TT, single factors and APC-R. DOAC-Remove™ has no significant effect on coagulation factors. For *in vitro* Use Only.

Presentation: 20 (A), 50 (B) or 250 (C) tablets in a vial. Ready to use. Contains activated carbon, specially formulated with additives.


Storage: Store in a dry place at ambient (15-25°C) in its original packaging.

Analytical Data:

	<u>Specification</u>	<u>Results</u>
Weight (n=100):	18 - 22 mg/tablet	pass
Rivaroxaban binding:	≥ 1200 ng/mL	pass
Dabigatran binding:	≥ 1200 ng/mL	pass

2018-04-17

Signed,


Urs Peter Geiger